Skip to content

Ayurvedic Rasayana therapies

A randomized placebo controlled multicentric study to evaluate the efficacy and safety of Ayurvedic formulation as an immunomodulator in reducing the risk of COVID 19 infection or severe stage coronavirus disease in Healthcare workers involved in care of patients with Coronavirus disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026700
Enrollment
200
Registered
2020-07-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Ayurveda formulation: Capsule Pranvir : 2 capsules twice daily with warm water. Capsule Yasada Rasayana: 1 capsule twice daily with warm waterfor 60 days Control Intervention1: Placebo:

Sponsors

Ayurved Rasayani
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 18 years or older 2 If an individual has come in close contact with someone who has been diagnosed with COVID 19 with last exposure within the last 4 days and do not have any symptoms or 3 A healthcare worker involved in care of patients with Coronavirus disease

Exclusion criteria

Exclusion criteria: 1 Immunocompromised patients or patients receiving immuno-compromised medications 2 Patients with active malignancy or undergoing anticancer therapies 3 Pregnant women or women who are breastfeeding 4 Consideration by the investigator for any reason that the subject is an unsuitable 5 candidate to receive study treatment Patients not willing to participate in study

Design outcomes

Primary

MeasureTime frame
To evaluate if Ayurveda Rasayana therapy can prevent symptomatic coronavirus disease or severe corona virus disease after known exposure to the SARS-CoV-2 coronavirusTimepoint: Day 1 Day 30 and Day 60

Secondary

MeasureTime frame
Evaluation of Pro inflammatory cytokines. Disease severity on an ordinal scale. Length of time to clinical improvement and clinical progression Evaluation of D-dimer Length of time to normalization of fever, normalization of oxygen Duration of supplemental oxygen and /mechanical ventilation Number of participants that developed ARDS Duration required to get COVID-19 PCR test negative Duration of hospitalization /or ICU stay Percent mortality Timepoint: Till day 60

Countries

India

Contacts

Public ContactDr Avinash Kadam

Ayurved Rasayani

avinashk@rbpl.co.in9970259583

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026